A case of recurrent and synchronous fibrous hamartoma of infancy.

Department of Paediatric Surgery, National Okayama Medical Centre, 1711-1, Tamasu, Okayama City, Okayama 701-1192, Japan.
Pediatric Surgery International (Impact Factor: 1.06). 03/2005; 21(2):119-20. DOI: 10.1007/s00383-004-1357-6
Source: PubMed

ABSTRACT We retrospectively reviewed the chart of a patient with recurrent fibrous hamartoma of infancy (FHI). This lesion presented as a gradually enlarging mass on the child's buttock. The child, a 6-month-old male, was followed up, and at 19 months of age the mass was excised. Eighteen months after the initial operation, a local recurrence was noticed. Forty-one months after the initial operation, reexcision was performed. Both masses demonstrated the characteristic features of FHI, which should be considered in the differential diagnosis of subcutaneous mass in young children.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Only a few published case of fibrous hamartoma of infancy (FHI) have commented on the changes in the overlying skin. There are descriptions of individual cases with cutaneous hyperpigmentation, hypertrichosis and hyperhidrosis. It is interesting to describe our case because, to our knowledge, the altered pigmentation of the overlying skin, with hairs on the surface, and eccrine gland hyperplasia combined with abortive hair follicles has not been reported together in association with the FHI. We recommend that all the biopsies must be excisional including overlying skin, thus the epidermal and dermal adnexal changes can be assessed in the microscopic evaluation which could have relevant implications from clinical and embryological point of view.
    Indian Journal of Dermatology 01/2013; 58(2):160. DOI:10.4103/0019-5154.108089
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fibrous hamartoma of infancy is a rare fibrous tumor of the subcutaneous tissue in infants. While most case reports focus on the unique histologic appearance, which has traditionally been relied upon for diagnosis, there are few reports in the radiology literature of its appearance at MR imaging. In this report, the authors present the case of a 9-month-old male who presented with a soft tissue mass on the shoulder. The MRI findings in benign fibrous hamartoma of infancy parallel the three components of the lesion seen histologically, with an organized arrangement of fat interspersed among heterogeneous soft tissue bands composed of mesenchymal and fibrous tissue. When present, this characteristic appearance may allow the diagnosis to be suggested preoperatively.
    Skeletal Radiology 06/2014; 43(11). DOI:10.1007/s00256-014-1940-4 · 1.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 53-year-old Caucasian male suffering from idiopathic dilated cardiomyopathy underwent cardiac transplantation. Fifty-seven days following transplant, he developed posttransplant lymphoproliferative disorder (PTLD), which was Epstein-Barr virus positive. The initial episode of PTLD was treated with a dose reduction in cyclosporine (CsA) and a 4-week course of rituximab. Subsequent biopsies showed resolution of PTLD. One year posttreatment, his evaluation revealed severe cardiac allograft vasculopathy (CAV). The patient was switched to sirolimus-based immunosuppression regimen with gradual up-titration of sirolimus in combination with complete withdrawal of previously administered Calcineurin-based immunosuppression approach. The switchover was carried out over a 6-week period. In the following 3 years, there was CAV regression as well as PTLD remission, without any significant episode of rejection. Despite frequent relapses with this form of PTLD, the patient remains in remission, 8 years posttransplantation. In summary, sirolimus has been demonstrated to attenuate the progression of CAV, and this case report illustrates that regression of CAV is possible. In addition to preventing rejection, mammalian target of rapamycin inhibitors directly suppress signaling pathways leading to PTLD and may be effective monotherapy for preventing rejection and suppressing PTLD.
    Transplantation Proceedings 06/2011; 43(5):1893-9. DOI:10.1016/j.transproceed.2011.03.033 · 0.95 Impact Factor